Home  /  Resource Library  /  Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

Results of a pharmacokinetic study examining ibrutinib combined with rituximab and bendamustine for treatment of MCL.